Business, energy, technology, markets and global industry news from Business News Today

ICONIC-TOTAL

PharmaDeviceNews ICONIC-TOTAL
Psoriasis treatment innovation moves closer to market as the US Food and Drug Administration grants Priority Review to Takeda’s zasocitinib following positive Phase 3 trial results, including head-to-head superiority over deucravacitinib in plaque psoriasis. Representative image.
Pharma & Biotech

Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis

Johnson & Johnson reports two-year ICOTYDE psoriasis results, with over 72% achieving PASI 90. See what the data mean for treatment.

Read More